Herbert Schmid
Novartis (Switzerland)(CH)Novartis Institutes for BioMedical ResearchNewcastle University(GB)
Publications by Year
Research Areas
Neuroendocrine Tumor Research Advances, Pituitary Gland Disorders and Treatments, Growth Hormone and Insulin-like Growth Factors, Neuroendocrine regulation and behavior, Neuroscience of respiration and sleep
Most-Cited Works
- → Opportunities in somatostatin research: biological, chemical and therapeutic aspects(2003)551 cited
- → Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase(2011)487 cited
- → Improving Oral Bioavailability of Peptides by Multiple N‐Methylation: Somatostatin Analogues(2008)365 cited
- → Pasireotide (SOM230): Development, mechanism of action and potential applications(2007)286 cited
- → Pharmacological targeting of the protein synthesis mTOR /4E‐ BP 1 pathway in cancer‐associated fibroblasts abrogates pancreatic tumour chemoresistance(2015)194 cited
- → Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro(2008)166 cited